About
Technology
Issues
FAQ
Links
Official Page
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.